Study: Coated stents aren't cost-effective

If drug-eluting stents were on the shelves at Costco, most value-conscious customers wouldn't buy. A new Swiss study has found that the coated stents aren't cost-effective for most patients--and wouldn't be even if prices were cut substantially. In fact, it would be "almost impossible" for the more expensive stents to become cost-effective in low-risk patients. That doesn't hold out much hope to manufacturers Johnson & Johnson and Boston Scientific.

But here's one positive to comfort stent makers. They're a good value for a subset of high-risk patients, concluded the study, published in this week's The Lancet. In these patients, who had small-vessel or bypass-graft stenting, the drug-coated versions were cost-effective. In some cases, the coated stents saved money that would have been spent treating complications.

-read The Lancet's release about the study

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.